A comparison of strontium ranelate and PTH(1-84)

References

• Quesada-Gómez JM, Muschitz C, Gómez-Reino J, Greisen H, Andersen HS, Dimai HP. The effect of PTH(1-84) or strontium ranelate on bone formation markers in postmenopausal women with primary osteoporosis: results of a randomized, open-label clinical trial. Osteoporos. Int. DOI: 10.1007/s00198-010-1460-6 (2010) (Epub ahead of print).
   Google Scholar
• Black DM, Bilezikian JP, Ensrud KE et al. One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis. N. Engl. J. Med.353, 555–565 (2005).
   PubMed Web of Science ®Google Scholar
• Meunier PJ, Roux C, Seeman E. et al. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N. Engl. J. Med.350, 459–468 (2004).
   PubMed Web of Science ®Google Scholar
• Meunier PJ, Slosman DO, Delmas PD et al. Strontium ranelate: dose-dependent effects in established postmenopausal vertebral osteoporosis – a 2-year randomized placebo controlled trial. J. Clin. Endocrinol. Metab.87, 2060–2066 (2002).
   PubMed Web of Science ®Google Scholar
• Henriksen K, Bollerslev J, Everts V, Karsdal MA. Osteoclast activity and subtypes as a function of physiology and pathology – implications for future treatments of osteoporosis. Endocr. Rev.32(1), 31–63 (2010).
   Google Scholar
• Reginster JY. Antifracture efficacy of currently available therapies for postmenopausal osteoporosis. Drugs71, 65–78 (2011).
   PubMed Web of Science ®Google Scholar
• Karsdal MA, Martin TJ, Bollerslev J, Christiansen C, Henriksen K. Are nonresorbing osteoclasts sources of bone anabolic activity? J. Bone Miner. Res.22, 487–494 (2007).
   PubMed Web of Science ®Google Scholar
• Reginster JY, Seeman E, de Vernejoul MC et al. Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study. J. Clin. Endocrinol. Metab.90, 2816–2822 (2005).
   PubMed Web of Science ®Google Scholar
• Arlot ME, Jiang Y, Genant HK et al. Histomorphometric and microCT analysis of bone biopsies from postmenopausal osteoporotic women treated with strontium ranelate. J. Bone Miner. Res.23, 215–222 (2008).
   PubMed Web of Science ®Google Scholar
• Recker RR, Marin F, Ish-Shalom S et al. Comparative effects of teriparatide and strontium ranelate on bone biopsies and biochemical markers of bone turnover in postmenopausal women with osteoporosis. J. Bone Miner. Res.24, 1358–1368 (2009).
   PubMed Web of Science ®Google Scholar
• Ostelo RW, Deyo RA, Stratford P et al. Interpreting change scores for pain and functional status in low back pain: towards international consensus regarding minimal important change. Spine (Phila Pa 1976)33, 90–94 (2008).
   PubMed Web of Science ®Google Scholar
• Lau AN, Ali SH, Sawka AM et al. Improvement in health-related quality of life in osteoporosis patients treated with teriparatide. BMC Musculoskelet. Disord.9, 151 (2008).
   PubMed Web of Science ®Google Scholar
• Black DM, Greenspan SL, Ensrud KE et al. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N. Engl. J. Med.349, 1207–1215 (2003).
   PubMed Web of Science ®Google Scholar
• Marquis P, Roux C, de la Loge C et al. Strontium ranelate prevents quality of life impairment in post-menopausal women with established vertebral osteoporosis. Osteoporos. Int.19, 503–510 (2008).
   PubMed Web of Science ®Google Scholar
• Henriksen K, Bay-Jensen AC, Christiansen C, Karsdal MA. Oral salmon calcitonin – pharmacology in osteoporosis. Expert Opin. Biol. Ther.10, 1617–1629 (2010).
   PubMed Web of Science ®Google Scholar
• Eisman JA, Bone HG, Hosking DJ et al. Odanacatib in the treatment of postmenopausal women with low bone mineral density: three-year continued therapy and resolution of effect. J. Bone Miner. Res.26(2), 242–251 (2010).
   Web of Science ®Google Scholar
• Lewiecki EM. Sclerostin monoclonal antibody therapy with AMG 785: a potential treatment for osteoporosis. Expert Opin. Biol. Ther.11, 117–127 (2011).
   PubMed Web of Science ®Google Scholar
• Finkelstein JS, Wyland JJ, Lee H, Neer RM. Effects of teriparatide, alendronate, or both in women with postmenopausal osteoporosis. J. Clin. Endocrinol. Metab.95(4), 1838–1845 (2010).
   PubMed Web of Science ®Google Scholar
• Karsdal MA, Leeming DJ, Dam EB et al. Should subchondral bone turnover be targeted when treating osteoarthritis? Osteoarthritis Cartilage16, 638–646 (2008).
   PubMed Web of Science ®Google Scholar
• Alexandersen P, Karsdal MA, Qvist P, Reginster JY, Christiansen C. Strontium ranelate reduces the urinary level of cartilage degradation biomarker CTX-II in postmenopausal women. Bone40, 218–222 (2007).
   PubMed Web of Science ®Google Scholar
• Bruyere O, Delferriere D, Roux C et al. Effects of strontium ranelate on spinal osteoarthritis progression. Ann. Rheum. Dis.67, 335–339 (2008).
   PubMed Web of Science ®Google Scholar